231 related articles for article (PubMed ID: 21824521)
1. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.
Thambisetty M; An Y; Kinsey A; Koka D; Saleem M; Güntert A; Kraut M; Ferrucci L; Davatzikos C; Lovestone S; Resnick SM
Neuroimage; 2012 Jan; 59(1):212-7. PubMed ID: 21824521
[TBL] [Abstract][Full Text] [Related]
2. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.
Thambisetty M; Simmons A; Velayudhan L; Hye A; Campbell J; Zhang Y; Wahlund LO; Westman E; Kinsey A; Güntert A; Proitsi P; Powell J; Causevic M; Killick R; Lunnon K; Lynham S; Broadstock M; Choudhry F; Howlett DR; Williams RJ; Sharp SI; Mitchelmore C; Tunnard C; Leung R; Foy C; O'Brien D; Breen G; Furney SJ; Ward M; Kloszewska I; Mecocci P; Soininen H; Tsolaki M; Vellas B; Hodges A; Murphy DG; Parkins S; Richardson JC; Resnick SM; Ferrucci L; Wong DF; Zhou Y; Muehlboeck S; Evans A; Francis PT; Spenger C; Lovestone S
Arch Gen Psychiatry; 2010 Jul; 67(7):739-48. PubMed ID: 20603455
[TBL] [Abstract][Full Text] [Related]
4. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease.
Mullan GM; McEneny J; Fuchs M; McMaster C; Todd S; McGuinness B; Henry M; Passmore AP; Young IS; Johnston JA
Curr Alzheimer Res; 2013 Nov; 10(9):973-8. PubMed ID: 24117116
[TBL] [Abstract][Full Text] [Related]
5. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
[TBL] [Abstract][Full Text] [Related]
7. Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD.
Spulber G; Niskanen E; Macdonald S; Kivipelto M; Padilla DF; Julkunen V; Hallikainen M; Vanninen R; Wahlund LO; Soininen H
Curr Alzheimer Res; 2012 May; 9(4):516-24. PubMed ID: 22191564
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
9. Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease.
Hänggi J; Streffer J; Jäncke L; Hock C
J Alzheimers Dis; 2011; 26(4):719-34. PubMed ID: 21709375
[TBL] [Abstract][Full Text] [Related]
10. Plasma Clusterin as a Potential Link Between Diabetes and Alzheimer Disease.
Ha J; Moon MK; Kim H; Park M; Cho SY; Lee J; Lee JY; Kim E
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32561922
[TBL] [Abstract][Full Text] [Related]
11. Associations of plasma clusterin and Alzheimer's disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study.
Haight T; Bryan RN; Meirelles O; Tracy R; Fornage M; Richard M; Nasrallah I; Yaffe K; Jacobs DR; Lewis C; Schreiner P; Sidney S; Davatzikos C; Launer LJ
PLoS One; 2018; 13(1):e0190478. PubMed ID: 29324756
[TBL] [Abstract][Full Text] [Related]
12. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
13. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.
Chiu MJ; Chen YF; Chen TF; Yang SY; Yang FP; Tseng TW; Chieh JJ; Chen JC; Tzen KY; Hua MS; Horng HE
Hum Brain Mapp; 2014 Jul; 35(7):3132-42. PubMed ID: 24129926
[TBL] [Abstract][Full Text] [Related]
14. Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer's disease: A longitudinal study.
Liu G; Liu C; Qiu A;
Hum Brain Mapp; 2021 Jun; 42(9):2931-2940. PubMed ID: 33739550
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
16. Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia.
Bartel F; Visser M; de Ruiter M; Belderbos J; Barkhof F; Vrenken H; de Munck JC; van Herk M;
Neuroimage Clin; 2019; 23():101902. PubMed ID: 31233953
[TBL] [Abstract][Full Text] [Related]
17. Impacts of CD33 Genetic Variations on the Atrophy Rates of Hippocampus and Parahippocampal Gyrus in Normal Aging and Mild Cognitive Impairment.
Wang WY; Liu Y; Wang HF; Tan L; Sun FR; Tan MS; Tan CC; Jiang T; Tan L; Yu JT;
Mol Neurobiol; 2017 Mar; 54(2):1111-1118. PubMed ID: 26803496
[TBL] [Abstract][Full Text] [Related]
18. MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease.
Devanand DP; Bansal R; Liu J; Hao X; Pradhaban G; Peterson BS
Neuroimage; 2012 Apr; 60(3):1622-9. PubMed ID: 22289801
[TBL] [Abstract][Full Text] [Related]
19. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
[TBL] [Abstract][Full Text] [Related]
20. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.
Mattsson N; Insel P; Tosun D; Zhang J; Jack CR; Galasko D; Weiner M;
PLoS One; 2013; 8(12):e85443. PubMed ID: 24392009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
